Medicure Inc.

Medicure Inc. (TSX:MPH/Amex: MCU) is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. The Company's lead drug, MC-1, is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. The cardiovascular and stroke market is the largest pharmaceutical sector with annual global sales of over US $70 billion. The Company's second product candidate, MC-4232, is being targeted for the treatment of hypertension and related, co-existing conditions. Hypertension is a common disorder in which blood pressure remains abnormally high. Approximately 73% of the more than 50 million adult Americans who have hypertension, are not adequately ( www.medicure.com )